Evaluate the Impact of a Specific Risk Prevention Program Associated With a Therapeutic Patient Education Program on the Risk Behaviors of Adult Patients With Uncontrolled Epilepsy.

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Pilot, controled, randomized study aiming to evaluate a plan for the prevention of risks related to epilepsy, 3 months after the last therapeutic patient education session. Two groups of patients will be compared: group intervention (consultation with the neurologist then a psychologist followed by a session dedicated to risk prevention (Recognize and Manage risks) integrated into usual Therapeutic Patient Education (TPE) versus control group (usual consultations with the neurologist and usual TPE). 37 subjects per group will be included in this study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• Patient between 18 and 60 years old

• Patient with poorly controlled epilepsy (persistence of seizures evolving for more than a year despite proper treatment) or patient seizure-free for over a year but for whom therapeutic patient education (TPE) would be beneficial according to the investigator..

• Patient agreeing to participate in a therapeutic education program (TPE)

Locations
Other Locations
France
CHU Gui de Chauliac
RECRUITING
Montpellier
Contact Information
Primary
Christiane Maurin, Nurse
c-maurin@chu-montpellier.fr
04.67.33.78.78
Time Frame
Start Date: 2024-04-16
Estimated Completion Date: 2028-04-16
Participants
Target number of participants: 74
Treatments
Experimental: Experimental group
Patients of the experimental group will have therapeutic patient education sessions that include one Recognizing and Managing the Risks of Epilepsy workshop.
Other: Control group Usual management
Patients of the control group will have the usual therapeutic patient education sessions.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov